Feasibility and Safety Study to Evaluate the Neuroprotective Effect of Hemodialysis in Acute Ischemic Stroke (DIAGLUICTUS2)

Feasibility, Safety, Randomized, Controlled, Open-label Study to Evaluate the Neuroprotective Effect of Hemodialysis of Plasma Glutamate and Proinflammatory Cytokines in the Acute Phase of Ischemic Stroke

Hemodialysis is a therapeutic strategy used in subjects with chronic renal failure. Our working hypothesis is based on results published in experimental animal models of stroke where the investigators have demonstrated that peritoneal dialysis is an effective technique to reduce blood glutamate levels and reduce infarct volume.

The objective of this clinical trial is to evaluate the viability, safety and efficacy of hemodialysis in patients with acute ischemic stroke, proposing that it may have a) a potential neuroprotective effect by reducing the excitotoxic levels of glutamate and proinflammatory cytokines in blood and b) fewer technical problems than peritoneal dialysis to apply in usual clinical practice.

Study Overview

• Status: Recruiting
• Conditions: Cerebrovascular Stroke
• Intervention / Treatment: Device: Hemodialysis

Detailed Description

The reason for the present study is based on previous data from the group that demonstrated the following results: a) The decrease in plasma Glu, by peritoneal dialysis (PD), reduces the size of the brain infarct in a model of focal cerebral ischemia in rats; b) PD is effective in reducing plasma Glu levels in patients with chronic renal failure; c) PD is a safe and well tolerated procedure in patients with ischemic stroke in the acute phase, however, it was not a viable procedure in our conditions, due to the malfunction of the automatic system that made it difficult for the inclusion sessions and dialysate extraction and the difficulty for the collaboration of this type of patient with the procedure; d). The increase in the median concentration of Glu after cerebral infarction was reduced to 46% after PD.

Based on our previous results, the investigators believe that hemodialysis may have fewer technical problems than PD and serve as a neuroprotection technique by lowering the levels of Glu and proinflammatory cytokines in blood. To do this, the investigators establish the following objectives: a) To evaluate the feasibility and safety of a hemodialysis procedure in patients with acute ischemic stroke compared to a control group; b) To analyze the clinical benefit of hemodialysis estimated by the volume of the infarction and the neurological and functional situation of the patients; and c) To measure the levels of glutamate and proinflammatory cytokines in plasma and dialysate samples. For this, a single-center, randomized, open-label, controlled study has been designed with a group of patients with ischemic stroke who receive conventional treatment (N=10) or conventional treatment + 2 hemodialysis sessions (N=10) in the acute phase of the stroke (Phase IIa clinical trial with medical device).

• Study Type: Interventional
• Enrollment (Anticipated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Monica Sobrado, PhD; Phone Number: +34915202416; Email: sobrado.m@gmail.com
• Study Contact Backup: Name: Carmen Ramos, MD; Phone Number: +34915202416; Email: cramosmartin90@gmail.com

Study Locations

• Spain
  • Madrid, Spain, 28006
    • Recruiting
    • José Vivancos Mora, MD., PhD
    • Contact: Mónica Sobrado, PhD; Phone Number: 915202416; Email: sobrado.m@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients older than 18 years.
2. Acute ischemic stroke confirmed by multimodal CT due to occlusion of a large caliber artery in the intracranial internal carotid and / or M1 and / or tandem half-portion cerebral artery.
3. ASPECTS between 4-10 in the CT scan without contrast of admission.
4. Patients should be treated by mechanical thrombectomy, with or without prior treatment with rtPA-iv, with a final >=TICI 2b result.
5. Patients to whom pharmacological thrombolytic treatment (rt-PA) and/or mechanical thrombectomy is applied and their NIHSS is ≥ 8 at 60 minutes having completely finished the reperfusion treatment performed.
6. <12 h from the onset of symptoms to the start of treatment by hemodialysis or the inclusion in the arm of conventional medical treatment. Those patients with uncertain or unknown time of onset of symptoms may be included in the study provided that the same in the multimodal CT scan is> = 50%
7. The participants have granted their consent.

Exclusion Criteria:

1. Patients with prior important functional dependence (mRS> 3);
2. Presence of a minor neurological deficit (NIHSS scale< 8 at the time of randomization);
3. Coma state;
4. Ischemic stroke of posterior territory;
5. Hemorrhagic stroke in the neuroimaging test performed at the beginning;
6. Pregnancy or lactation (urinalysis will be performed prior to randomization in women of childbearing age);
7. Hematological, infectious, inflammatory or chronic neoplastic diseases known at the time of treatment;
8. Patients with severe chronic renal failure on hemodialysis (stage 5D)
9. Severe liver disease (ascites or coagulopathy, for example);
10. Any serious, advanced or terminal illness with an expected life expectancy of less than 6 months;
11. Any comorbidity situation that, at the discretion of the investigator, may prevent the patient from completing the study;
12. Stroke or myocardial infarction in the previous 90 days;
13. Platelet count <100,000 / mm3;
14. Anticoagulated patients who, in the opinion of the Nephrologist, the establishment of the central route for performing hemodialysis poses a high risk of bleeding;
15. Participation in another clinical trial in the previous 90 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: hemodialysis group; The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke. The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers.	Device: Hemodialysis; Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure. Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer. This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances.; Other Names: extracorporeal blood purification technique
No Intervention: control group; The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Safety Endpoint: Percentage estimation of mortality	Reported here is the percentage of participants who died due to any cause during the study. Mortality will be compared between randomized groups in an intention-to-treat fashion	Day 90
Primary Safety Endpoint: Number of adverse effects	An adverse event (AE) is defined as an undesirable medical occurrence in a participant of clinical research that does not necessarily have a causal relationship with this treatment. An AE can be a sign, symptom, laboratory finding, or result of an abnormal test. Adverse effects number will be compared between randomized groups in an intention-to-treat fashion	Day 90
Primary Safety Endpoint: Percentage of participants with early neurological impairment	Early neurological impairment: Increase of 4 or more points on the NIHSS scale during the first 24 hours after treatment. The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. NIHSS score will be compared between randomized groups in an intention-to-treat fashion	Day 7
Primary Safety Endpoint: Percentage of participants with symptomatic bleeding transformation	The incidence rate of intracranial hemorrhages on follow-up CT. The incidence rate will be compared between randomized groups in an intention-to-treat fashion	Day 3
Feasibility of hemodialysis procedure in stroke: participant adherence to hemodialysis procedure.	The study will be considered viable if the percentage of patients who complete their hemodialysis procedure is equal to or greater than 70%.	Day 3
Feasibility of hemodialysis procedure in stroke: Time of intervention	The study will be considered viable if, in at least 80% of patients, the time from randomization to the start of the hemodialysis treatment is not more than 2h.	Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of the first haemodialysis in the reduction of plasma Glu	Time course of Glu concentrations in plasma on each experimental arm. The first hemodialysis will be before 12 h from the start of the symptoms (if start is known) or before 12 h from the last time seen well (if start is not known). The first sample obtained will be assigned the time 0h of the first hemodialysis. Glu concentrations will be compared between randomized groups in an intention-to-treat fashion	Hour 0, hour 0.5, hour 3, hour 3.5
Efficacy of the first haemodialysis in the reduction of plasma pro-inflammatory cytokines	Time course of pro-inflammatory cytokines (IL1, IL6, IL8 and TNFalpha) concentrations in plasma on each experimental arm. The first hemodialysis will be before 12 h from the start of the symptoms (if start is known) or before 12 h from the last time seen well (if start is not known). The first sample obtained will be assigned the time 0h of the first hemodialysis. Pro-inflammatory cytokines will be compared between randomized groups in an intention-to-treat fashion	Hour 0, hour 0.5, hour 3, hour 3.5
Efficacy of the second haemodialysis in the reduction of plasma Glu	Time course of Glu concentrations in plasma on each experimental arm. The second hemodialysis will be when the onset of symptoms is known: 24±3h from the onset of symptoms or, when the onset of symptoms is not known: 8-12h from the onset of the first HD. The first sample obtained will be assigned the time 0h of the second hemodialysis. Glu concentrations will be compared between randomized groups in an intention-to-treat fashion	Hour 0, hour 0.5, hour 3, hour 3.5
Efficacy of the second haemodialysis in the reduction of plasma pro-inflammatory cytokines	Time course of pro-inflammatory cytokines concentrations (IL1, IL6, IL8 and TNFalpha) in plasma on each experimental arm. The second hemodialysis will be when the onset of symptoms is known: 24±3h from the onset of symptoms or, when the onset of symptoms is not known: 8-12h from the onset of the first HD. The first sample obtained will be assigned the time 0h of the second hemodialysis. Pro-inflammatory cytokines will be compared between randomized groups in an intention-to-treat fashion	Hour 0, hour 0.5, hour 3, hour 3.5
Efficacy of haemodialysis in the reduction of infarct volume	The change in infarct volume measured as the difference between the infarct core on multimodality CT input and infarct volume at 24±8h and 72h ±24h minus the infarct volume measured at input on single CT images will be calculated. Infarct volume will be compared between randomized groups in an intention-to-treat fashion	Day 1, day 3
Percentage of participants with favourable evolution of the neurological deficit	The favourable evolution in the neurological deficit (NIHSS 0.1 or improvement ≥ 4 points) will be assessed with respect to that obtained 60 minutes after the complete completion of the reperfusion treatment carried out. The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. The neurological deficit score will be compared between randomized groups in an intention-to-treat fashion	Day 7
Percentage of participants with good functional recovery as assessed by the Modified Rankin Scale	The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. A score of 0-2 represents good functional recovery. The scores are defined as follows: (0) No symptoms at all; (1) No significant disability despite symptoms, able to carry out all usual duties and activities; (2) Slight disability, unable to carry out all previous activities, but able to look after own affairs without assistance. The mRS score will be compared between randomized groups in an intention-to-treat fashion	Month 3.

Collaborators and Investigators

• Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
• Investigators: Principal Investigator: José Vivancos, MD,PhD, Instituto de Investigación Hospital la Princesa

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Anticipated): November 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: February 4, 2020
• First Submitted That Met QC Criteria: March 3, 2020
• First Posted (Actual): March 5, 2020

Study Record Updates

• Last Update Posted (Actual): January 3, 2022
• Last Update Submitted That Met QC Criteria: December 30, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: clinical trial; proinflammatory cytokines; glutamate; safety and efficacy; hemodialysis neuroprotection
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Ischemic Stroke
• Other Study ID Numbers: JVM-HD-19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No